A novel FOXP1-PDGFRA fusion gene in myeloproliferative neoplasm with eosinophilia

Cancer Genet. 2015 Oct;208(10):508-12. doi: 10.1016/j.cancergen.2015.07.001. Epub 2015 Jul 14.

Abstract

We identified a novel fusion gene, FOXP1-PDGFRA, in a patient with myeloproliferative neoplasm (MPN) with eosinophilia, harboring the chromosome abnormality t(3;4)(p13;q12). The patient responded well to imatinib and has remained in molecular remission for 3 years. This is the seventh fusion gene involving PDGFRA in MPN with eosinophilia. PDGFRA was truncated in its autoinhibitory domain, as in other PDGFRA-related MPNs, and was fused to FOXP1 at its functional forkhead domain. Comparing genomic DNA with mRNA sequences provides the possibility that the splicing process near the breakpoint junction in the FOXP1-PDGFRA fusion gene may use the normal splice donor site for intron 23a of FOXP1 and the cryptic splice acceptor site in exon 12 of PDGFRA. This is the first report to describe the FOXP1-PDGFRA fusion gene in MPN.

Keywords: FOXP1-PDGFRA; Myeloproliferative neoplasm with eosinophilia; imatinib.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Cytogenetic Analysis
  • Forkhead Transcription Factors / genetics*
  • Humans
  • Hypereosinophilic Syndrome / drug therapy
  • Hypereosinophilic Syndrome / genetics*
  • Hypereosinophilic Syndrome / pathology
  • Imatinib Mesylate / therapeutic use
  • Leukemia
  • Male
  • Oncogene Proteins, Fusion / genetics
  • Oncogene Proteins, Fusion / metabolism*
  • Receptor, Platelet-Derived Growth Factor alpha / genetics*
  • Repressor Proteins / genetics*

Substances

  • Antineoplastic Agents
  • FOXP1 protein, human
  • Forkhead Transcription Factors
  • Oncogene Proteins, Fusion
  • Repressor Proteins
  • Imatinib Mesylate
  • Receptor, Platelet-Derived Growth Factor alpha

Supplementary concepts

  • Pdgfra-Associated Chronic Eosinophilic Leukemia